Boston Therapeutics, Inc. (BTHE) Research

Founded in 2009 and headquartered in Lawrence, Massachusetts, Boston Therapeutics, Inc. operates as a pre-clinical and clinical-stage pharmaceutical development firm. The company specializes in the development, manufacturing, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements within the United States. Its pipeline features several key drug candidates: BTI-320, a non-systemic carbohydrate compound currently in Phase IIb clinical trials, engineered to mitigate post-meal increases in blood glucose levels for patients with Type 2 diabetes and pre-diabetes; BTI-410, an injectable peptide compound that has completed Phase Ib clinical trials, developed for Type 1 immunosuppression therapy post-kidney transplant and for Type 2 diabetes patients; and IPOXYN, an injectable carbohydrate drug designed to prevent necrosis (cell death) and alleviate hypoxic conditions such as diabetic foot ulcers and other vascular/neurological complications. Furthermore, Boston Therapeutics markets SUGARDOWN, a non-systemic complex carbohydrate dietary supplement supporting healthy post-meal blood glucose levels. The company previously operated as Avanyx Therapeutics, Inc. before adopting its current name in November 2010.

Open Boston Therapeutics, Inc. (BTHE) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.